Drug Database · Clinicians

Furosemide + Potassium chloride

Also known as: frusemide (former British name, for furosemide)

Brands (1) Diumide-KShow all

Diuretic PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH productVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease US FDA label

  • Use: Klor-Con is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. US FDA label

    Kidney dosing: Potassium chloride (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Hypokalemia treatment: 40 to 100 mEq/day in divided doses, no more than 40 mEq per dose; prevention: about 20 mEq/day. Use IV potassium if serum potassium is below 2.5 mEq/L (label).
    CrCl 30–59 mL/min
    Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). IV concentrate: must be diluted; never IV push (see IV label).
    CrCl 15–29 mL/min
    Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). IV concentrate: must be diluted; never IV push (see IV label).
    CrCl <15 mL/min (not on dialysis)
    Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). Specialist input. IV concentrate: must be diluted; never IV push (see IV label).
    Hemodialysis (intermittent)
    No dialysis dose in label; potassium removal depends on the dialysate. Give only for documented hypokalemia, start low and check potassium frequently (label 8.7); specialist input. IV concentrate (2 mEq/mL) must be diluted before use; never give by IV push or undiluted (fatal arrhythmia and cardiac arrest reported). In kidney impairment potassium is retained: use the low end of the infusion rate in the IV product label, with ECG monitoring as needed, and recheck potassium after each replacement. Concentration and rate limits: see the IV product label.
    Peritoneal dialysis
    No PD dose in label. PD patients can become hypokalemic; replace by measured potassium, starting low (label 8.7); specialist input. Hypokalemia is a modifiable risk factor for PD peritonitis (ISPD 2022).
    CRRT
    No data in label; replacement guided by frequent potassium levels and CRRT fluid potassium. Specialist input.
    • Dialyzable? Potassium is removed by hemodialysis and peritoneal dialysis (label lists dialysis among hyperkalemia treatments).
    • Monitoring Serum potassium frequently in kidney impairment and periodically on maintenance; kidney function; magnesium, acid-base status and ECG in cardiac or kidney disease (label 2.1, 8.7).

    From the Potassium chloride monograph (renalcarematters.com, reviewed).

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 40 mg/600 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Furosemide + Potassium chloride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Furosemide + Potassium chloride
Package insert
Diumide-KFurosemide + Potassium Chloride
40mg/600 mg Film-coated TabletFoil Strip x 10's (Box of 50's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Pascual Pharma Corp.
DR-XY2615
May 9, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .